Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(S)-UFR2709 is a competitive antagonist of the nicotinic acetylcholine receptor (nAChR), exhibiting a greater affinity for α4β2 nAChRs compared to α7 nAChRs. It effectively reduces anxiety and ethanol consumption, as well as ethanol preference, in alcohol-preferring rats. Additionally, (S)-UFR2709 functions as an anxiolytic agent and holds the potential for investigating nicotine addiction.
产品描述 | (S)-UFR2709 is a competitive antagonist of the nicotinic acetylcholine receptor (nAChR), exhibiting a greater affinity for α4β2 nAChRs compared to α7 nAChRs. It effectively reduces anxiety and ethanol consumption, as well as ethanol preference, in alcohol-preferring rats. Additionally, (S)-UFR2709 functions as an anxiolytic agent and holds the potential for investigating nicotine addiction. |
体外活性 | Brain nicotinic acetylcholine receptors (nAChRs) is a heterogeneous family of pentameric acetylcholine-gated cation channels, which is a molecular target for the treatment of alcohol abuse and dependence[1]. |
体内活性 | (S)-UFR2709 (50-100 μg/ml; 3 min and then maintained for another 5 min in a holding tank before testing the swimming behaviour in the test tank for a period of 5 min) produces a decrease in the bottom dwelling for NTT test, and UFR2709 induces a significant and dose-dependent decrease in bottom dwelling time to 52.9 and 87.0 s, respectively at 50 and 100 μg/ml[2].(S)-UFR2709 (50-100 μg/ml) decreases nicotine-evoked mRNA expression of α4 nACh receptor subunit, but UFR2709 has less effect on α4 nACh receptor subunit in the brain of adult zebrafish[2].(S)-UFR2709 (intraperitoneal?injection; 1-10 mg/kg; daily; 17 days) reduces ethanol consumption and ethanol preference and increased water consumption in a dose-dependent manner. The most effective dose of UFR2709 is 2.5 mg/kg, it induces a 56% reduction in alcohol consumption.?(S)-UFR2709 does not affect the weight or locomotor activity of the rats[1]. Animal Model: High-alcohol-drinking UChB rats[1]Dosage: 10 mg/kg, 5 mg/kg, 2.5 mg/kg, or 1 mg/kg Administration: Intraperitoneal?injection; 1-10 mg/kg; daily; 17 days Result: Did not affect the weight or locomotor activity and reduced ethanol consumption and preference. |
别名 | (S)-UFR2709 |
分子量 | 219.284 |
分子式 | C13H17NO2 |
CAS No. | 1431628-22-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
(S)-UFR2709 1431628-22-6 (S) UFR2709 (S)UFR2709 UFR-2709 UFR2709 UFR 2709 (S)-UFR-2709 Inhibitor inhibitor inhibit